Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Public ClinicalTrials.gov record NCT05461430. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
Study identification
- NCT ID
- NCT05461430
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Travera Inc
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
- Ascites, Malignant
- Carcinoma
- Carcinoma Bladder
- Carcinoma Breast
- Carcinoma of Esophagus
- Carcinoma of Unknown Primary
- Carcinoma of the Anus
- Carcinoma of the Appendix
- Carcinoma of the Bladder
- Carcinoma of the Cervix
- Carcinoma of the Head and Neck
- Carcinoma of the Larynx
- Carcinoma of the Nasopharynx
- Carcinoma of the Oral Cavity
- Carcinoma of the Oropharynx
- Carcinoma of the Penis
- Carcinoma of the Vulva
- Carcinoma, Hepatocellular
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian
- Carcinoma, Pancreatic
- Carcinoma, Pancreatic Ductal
- Carcinoma, Renal
- Carcinoma, Renal Cell
- Carcinoma, Small Cell
- Carcinoma, Thymic
- Cholangiocarcinoma
- Melanoma
- Mesothelioma
- Pancreatic Cancer
- Pleural Effusion, Malignant
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2022
- Primary completion
- Mar 22, 2026
- Completion
- Mar 22, 2026
- Last update posted
- Apr 12, 2026
2022 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| xCures | Oakland | California | 94612 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05461430, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05461430 live on ClinicalTrials.gov.